<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080323</url>
  </required_header>
  <id_info>
    <org_study_id>dinoprostone hysterectomy</org_study_id>
    <nct_id>NCT04080323</nct_id>
  </id_info>
  <brief_title>Single-dose Vaginal Dinoprostone and Hysterectomy</brief_title>
  <official_title>Effect of a Single Preoperative Dose of Vaginal Dinoprostone on Intraoperative Blood Loss During Abdominal Hysterectomy:a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we will assess the efficacy of dinoprostone in minimizing blood loss during
      hysterectomy when used as a single preoperative dose via the vaginal route. The reduction of
      blood flow may be due to the combined effect of myometrial contraction and vasoconstrictive
      effect
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 10, 2019</start_date>
  <completion_date type="Anticipated">December 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decrease blood loss during hysterectomy</measure>
    <time_frame>intraoperative</time_frame>
    <description>decrease blood loss during hysterectomy in ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative hemoglobin level</measure>
    <time_frame>24 hours</time_frame>
    <description>postoperative hemoglobin level in gm/dl</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hysterectomy</condition>
  <arm_group>
    <arm_group_label>dinoprostone 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 minutes before the surgery 3 mg of dinoprostone inserted vaginally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60 minutes before the surgery 1 tablet of placebo inserted vaginally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone 3 mg</intervention_name>
    <description>1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery</description>
    <arm_group_label>dinoprostone 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 vaginal tablet of placebo 60 minutes before surgery</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Patients presenting for hysterectomy for any benign indication including uterine
             fibroids.

               -  Age ≥ 18 years

               -  Pre-operative hemoglobin &gt;8 g/dl

               -  Willing to have dinoprostone or a placebo prior to hysterectomy

               -  Ability to understand and the willingness to sign a written informed consent.

        Exclusion Criteria:

          -  • Patients with known or suspected endometrial/ovarian/cervical cancer.

               -  Patients undergoing hysterectomy for endometrial hyperplasia or cervical
                  dysplasia.

               -  Patients currently undergoing treatment for any type of cancer.

               -  Patients with known bleeding/clotting disorders or a history of thromboembolism
                  (including deep venous thrombosis or pulmonary embolism)

               -  History of allergic reactions to dinoprostone.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED SAMY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AHMED SAMY</last_name>
    <phone>+201100681167</phone>
    <email>ahmedsamy8233@gmail.com</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Samy aly ashour</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

